Edition:
India

People: Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

13.46USD
18 Oct 2019
Change (% chg)

$-0.39 (-2.82%)
Prev Close
$13.85
Open
$13.72
Day's High
$13.81
Day's Low
$13.13
Volume
130,542
Avg. Vol
139,904
52-wk High
$23.01
52-wk Low
$12.69

Smith, David 

Mr. David V. Smith is Independent Director of the Company since March 2016. Mr. Smith brings to our board of directors extensive experience in financial management, corporate finance and corporate governance. Mr. Smith serves as Executive Vice President and Chief Financial Officer at Five Prime Therapeutics, a publicly traded company focused on discovering and developing novel immuno-oncology protein therapeutics. Previously, Mr. Smith served as Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology, until its acquisition by Thermo Fisher Scientific in March 2018. Prior to IntegenX, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation, a publicly-traded company focused on the development of advanced therapy options for the treatment of heart disease, from December 2006 until July 2011. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, which he joined in 1999, and where he held a number of positions of increasing responsibility, including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation. Mr. Smith previously served as chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.

Basic Compensation

Total Annual Compensation, USD 80,000
Restricted Stock Award, USD 84,995
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 164,995

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Bernard Kelley

204,995

John Nicols

3,438,810

Gordon Sangster

1,398,940

Laurie Heilmann

--

Thomas Baruch

154,995

Pam Cheng

169,995
As Of  31 Dec 2018